NCT05235074View on ClinicalTrials.gov

OH2 Oncolytic Viral Therapy in Central Nervous System Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

June 16, 2026

Study Completion Date

June 16, 2026

Conditions
Central Nervous System Tumors
Interventions
BIOLOGICAL

OH2 injection

OH2: Oncolytic Type 2 Herpes Simplex Virus

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

Sponsors
All Listed Sponsors
lead

Binhui Biopharmaceutical Co., Ltd.

INDUSTRY